secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065311
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia reports 2022 Auryxia revenue $177.1M (+24.5% YoY); net loss narrows to $92.6M
--------------------------------------------------------------------------------

- Q4 2022 net product revenue $49.7M (+18.1% YoY); full-year $177.1M, driven by pricing and payer mix.
- Full-year net loss $92.6M, down from $282.8M in 2021; cash $90.5M at year-end.
- Positive CHMP opinion for vadadustat (Vafseo) in Europe; potential EC approval by May 2023.
- 2023 Auryxia net product revenue guidance set at $175-180M, reflecting cautious market outlook.
- Regained vadadustat rights globally; submitted FDA Formal Dispute Resolution Request in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/0001193125-23-065311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/d367644d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer